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Trends in the Medical Management of Patients 
With Heart Failure
Samuel W. Joffea, b, Matthew DeWolfa, Jeffrey Shiha, David D. McManusa, b, 
Frederick A. Spencera, c, Darleen Lessardb, Joel M. Gorea, b, Robert J. Goldbergb, d
Abstract
Background: Despite the availability of effective therapies, heart 
failure (HF) remains a highly prevalent disease and the lead-
ing cause of hospitalizations in the U.S. Few data are available, 
however, describing changing trends in the use of various cardiac 
medications to treat patients with HF and factors associated with 
treatment. The objectives of this population-based study were to 
examine decade-long trends (1995 - 2004) in the use of several car-
diac medications in patients hospitalized with acute decompensated 
heart failure (ADHF) and factors associated with evidence-based 
treatment.
Methods: We reviewed the medical records of 9,748 residents of 
the Worcester, MA, metropolitan area who were hospitalized with 
ADHF at all 11 central Massachusetts medical centers in 1995, 
2000, 2002, and 2004.
Results: Between 1995 and 2004, respectively, the prescription 
upon hospital discharge of beta-blockers (23%; 67%), angioten-
sin pathway inhibitors (47%; 55%), statins (5%; 43%), and aspirin 
(35%; 51%) increased markedly, while the use of digoxin (51%; 
29%), nitrates (46%; 24%), and calcium channel blockers (33%; 
22%) declined significantly; nearly all patients received diuretics. 
Patients in the earliest study year, those with a history of obstructive 
pulmonary disease or anemia, incident HF, non-specific symptoms, 
and women were less likely to receive beta blockers and angioten-
sin pathway inhibitors than respective comparison groups. In 2004, 
82% of patients were discharged on at least one of these recom-
mended agents; however, only 41% were discharged on medica-
tions from both recommended classes.
Conclusions: Our data suggest that opportunities exist to further 
improve the use of HF therapeutics.
Keywords: Acute heart failure; Time trends; Population surveil-
lance
Introduction
Heart failure is a highly prevalent, morbid, and costly dis-
ease, affecting nearly 6 million Americans and causing more 
than 275,000 deaths annually [1]. Heart failure (HF) is also 
the leading cause of hospital admissions in the U.S.
Over the past 2 decades, numerous randomized con-
trolled trials have demonstrated improved survival in pa-
tients with HF with reduced ejection fraction (HFrEF) 
treated with beta blockers, angiotensin converting enzyme 
(ACE) inhibitors, and angiotensin receptor blockers (ARB’s) 
[2-8]. In certain populations, aldosterone antagonists and the 
combination of nitrates plus hydralazine have demonstrated 
important health benefits [9, 10]. Clinical trials have shown 
a lack of benefit on long-term survival in patients with HF 
treated with non-dihydropyridine calcium channel blockers 
or digoxin [11, 12], though the DIG study showed fewer re-
hospitalizations and enhanced patient exercise capacity with 
digoxin [11]. Although diuretics are a therapeutic mainstay 
in patients with HF, no large randomized controlled trial 
has been conducted demonstrating a survival benefit from 
the use of these agents. Aspirin and statins have been shown 
to increase survival in patients with coronary artery disease 
(with or without accompanying HF), but not in patients with 
non-ischemic HF [13].
The results of these trials and other evidence have been 
incorporated into the ACC/AHA Clinical Practice Guidelines 
for Congestive Heart Failure, which were first published in 
1995, with subsequent updates [14-17]. For patients with HF 
with reduced ejection fraction (HFrEF), beta blockers, ACE 
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Table 1. Demographic and Clinical Characteristics of Patients Hospitalized With Acute Heart Failure
Data are given as percentages or means unless otherwise noted.
Total Population
(n = 9,748)
1995 Cohort
(n = 1,949)
2004 Cohort
(n = 2,469)
Age (mean, years) 76.2 75.7 76.2
Age group (years) (%)
< 65 15.6 14.3 16.7
65 - 74 21.5 26.9 20.8
75 - 84 37.1 37.5 34.1
≥ 85 25.7 21.4 28.4
Male 43.9 42.9 46.9
Caucasian 93.8 96.8 92.3
Incident event 29.0 26.1 36.4
Length of hospital stay (days) 6.1 7.4 6.1
Physiologic Factors
Cholesterol (mg/dL) 163.1 178.9 149.9
Systolic blood pressure (mmHg) 142.9 146.3 140.6
Diastolic blood pressure (mmHg) 74.7 79.1 72.5
eGFR (mL/min/1.73 m2) 52.7 54.1 51.8
Glucose (mg/dL) 160.6 169.5 152.9
Medical History (%)
Anemia 24.6 21.9 26.7
Coronary heart disease 56.0 57.0 55.7
Chronic lung disease 35.9 35.5 35.7
Diabetes 39.0 39.7 39.3
Hypertension 68.7 62.3 72.8
Peripheral vascular disease 19.7 20.2 21.0
Renal failure 25.9 21.5 31.4
Stroke 13.2 14.3 11.5
Presenting Symptoms (%)
Angina/chest pain 31.2 31.2 29.9
Dyspnea/shortness of breath 93.4 96.5 92.2
Edema/swelling 70.3 63.8 72.7
Nausea/vomiting 16.0 14.2 17.1
Orthopnea 35.4 29.2 38.4
Weakness 25.1 24.9 23.8
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inhibitors, and ARB’s receive a Class I, level of evidence A 
recommendation. For patients with HF with preserved ejec-
tion fraction (HFpEF), a Class I recommendation is provided 
generically for the control of blood pressure and heart rate, 
with no medication classes specified. Beta blockers, ACE in-
hibitors, and ARB’s receive a Class IIb, level of evidence C 
recommendation, suggesting that these agents may be ben-
eficial, although definitive evidence is lacking.
Two large population-based studies evaluating the fre-
quency of hospitalizations for HF in the U.S. between 1970 
and 2000 found relatively stable hospitalization rates [18, 
19]. In contrast, a recent study of more than 55 million 
Medicare beneficiaries hospitalized with HF between 1998 
and 2008 showed a marked decrease in the hospitalization 
rate for HF over this period [20]. While the use of evidence-
based therapies to treat HF may have been partially respon-
sible for the observed decrease in HF-related hospitaliza-
tions, few data are available describing changing trends in 
the utilization of, and factors associated with, HF medica-
tions in a large, community-based population.
The primary objective of this study was to describe 
decade-long trends (1995 - 2004) in the prescribing of in-
patient and out-patient medications used to treat patients 
hospitalized with acute heart failure (ADHF). A secondary 
objective was to examine factors associated with the pre-
scribing of recommended cardiac medications.
Methods
The data for this study were derived from the Worcester 
Heart Failure Study, a population-based study of patients 
hospitalized with ADHF in the greater Worcester, MA, met-
ropolitan area [21-23]. This study was approved by the In-
stitutional Review Board at the University of Massachusetts 
Medical School.
The study sample consisted of greater Worcester resi-
dents hospitalized for possible ADHF during the 4 study 
years of 1995, 2000, 2002, and 2004. These years were 
selected to coincide with population census estimates and 
based on the availability of grant funding. Trained physi-
cians and nurses performed a standardized review of the 
medical records of greater Worcester residents hospitalized 
at 11 medical centers in central Massachusetts with Inter-
national Classification of Disease (ICD)-9 codes consistent 
with the presence of possible HF. A discharge diagnosis of 
HF (ICD-9 code 428) was the principal diagnostic category 
reviewed. In addition, the medical records of patients with 
additional discharge diagnoses were reviewed to identify 
patients who may have had new onset HF. The diagnosis of 
HF was confirmed based on use of the Framingham Study 
criteria [24]. We included in our study population patients 
with an initial (incident) episode of ADHF as well as those 
with previously diagnosed HF.
Data on patient demographics, medical history, clinical 
characteristics, presenting symptoms, laboratory and test re-
sults, as well as prescribing of cardiac medications on ad-
mission, during hospitalization, and at the time of hospital 
discharge were collected. Medications of interest included 
those shown to improve survival in patients with HFrEF 
(beta blockers, ACE inhibitors, ARBs, and aldosterone an-
tagonists), therapies designed to provide symptomatic relief 
(diuretics, digoxin, calcium channel blockers, and nitrates), 
and therapies shown to be beneficial in patients with HF due 
to coronary artery disease (aspirin and statins). We did not 
collect information on post-discharge medication use.
Data analysis
Chi square tests for trend were utilized to examine the sig-
nificance of changes in the prescribing of selected cardiac 
medications between 1995 and 2004. Chi-square tests were 
also used to evaluate differences in discrete variables, while 
t-tests were used to evaluate differences in continuous vari-
ables, between respective comparison groups. We used lo-
gistic multivariable regression modeling to evaluate the as-
sociation between various patient characteristics and the lack 
of treatment with the medications of interest. These variables 
were selected on the basis of the results of prior studies and 
on our observed univariate associations with the use of the 
different medications examined. We also used logistic re-
gression modeling to examine changing trends in hospital 
discharge medication use, relative to the referent year of 
1995, while simultaneously controlling for age, sex, race, 
history of several cardiovascular and noncardiovascular co-
morbidities, acute presenting symptoms, length of hospital 
stay, and several physiologic parameters (for example, esti-
mated GFR, blood pressure, serum glucose levels). Analysis 
of pre-hospital medications was only examined in patients 
with previously diagnosed HF (incident patients excluded), 
while the analysis of medications at the time of hospital dis-
charge was examined in hospital survivors only. We did not 
examine the association between the prescribing of selected 
medications and either hospital or post-discharge death rates 
due to the potential confounding for medication indication 
and due to the nonrandomized nature of this descriptive 
study. Ejection fraction (EF) findings were assessed in ap-
proximately one-third of study patients during their index 
hospitalization.
 
Results
The study population consisted of 9,748 adult residents of 
the Worcester metropolitan area hospitalized with ADHF. 
The mean age of this population was 76 years, 94% were 
Caucasian, 44% were male, and 71% had been previously 
diagnosed with HF. Many patients had important comorbidi-
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ties and most presented with dyspnea and edema (Table 1).
Patients hospitalized with ADHF in 2004 as compared 
to the initial study year of 1995 were more likely to be older, 
male, and non-Caucasian, to have a higher body mass in-
dex, lower blood pressure and serum cholesterol levels, and 
to present with an initial episode of ADHF (Table 1). They 
were also more likely to have a history of hypertension or 
renal insufficiency. Among the 3,611 patients who had EF in-
formation available, the average and median EF values were 
45% and 48%, respectively; among these patients, 1,786 
(49%) had EF findings of 50% and higher.
Trends in medication use
The use of beta blockers, angiotensin pathway inhibitors 
(ACE inhibitors and ARBs), statins, and aspirin during hos-
pitalization for ADHF increased markedly during the study 
period (Table 2). Between 1995 and 2004, the use of beta 
blockers increased nearly three -fold, the use of angiotensin 
pathway inhibitors increased from 50.4% to 60.7%, and the 
use of statins increased more than seven fold. Similar trends 
were noted for the prescribing of chronic pre-hospital (out-
patient) as well as discharge medications. The use of diuret-
ics was widespread and relatively constant during the years 
under study (Table 2). In contrast, the in-patient and out-pa-
tient use of digoxin, nitrates, and calcium channel blockers 
decreased markedly during the years under study.
Given the differences in recommended therapy for 
HFrEF compared to HFpEF, we examined trends treatment 
practices in these 2 groups (Table 3 and 4). In the 1,330 pa-
tients with HFrEF (HF ≤ 40%), there were marked increases 
in the administration of beta blockers, angiotensin pathway 
inhibitors, aspirin, and statins over time, in accordance with 
guidelines (Table 3). In the 1,786 patients with HFpEF (EF 
≥ 50%), there were substantial increases in the prescribing 
of beta blockers, angiotensin pathway inhibitors, aspirin and 
statins (Table 4), though of a lesser magnitude overall than 
in patients with HFrEF.
Given changing patient demographic and clinical char-
acteristics during the years under study, we examined chang-
ing trends in hospital discharge medication use while si-
multaneously controlling for a variety of demographic and 
clinical characteristics (Table 5). Compared to the referent 
year of 1995, patients hospitalized with ADHF in 2004 were 
significantly more likely to have been prescribed ACE in-
hibitors/ARBs, aspirin, beta blockers, and lipid lowering 
medication, and were significantly less likely to have been 
treated with calcium channel blockers, digoxin, and nitrates, 
at the time of hospital discharge. Relatively similar trends 
were observed in patients with HFpEF and HFrEF with these 
trends somewhat more pronounced in patients with HFrEF 
(Table 5).
Data on the use of aldosterone antagonists were only 
available for patients hospitalized in 2002 and 2004; approx-
imately 10% of patients with HF were treated with aldoste-
rone antagonists during these 2 years. Among patients with 
HFpEF, 6.5% of patients were treated with these agents in 
2002 and 2004 whereas 13.6% of patients with HFrEF were 
treated with aldosterone antagonists during these years.
Contraindications to treatment
To better understand the possible reasons for the lack of use 
of recommended medications in certain patients hospitalized 
with ADHF, we reviewed the charts of all study patients for 
contraindications to these agents. The frequency of listed al-
lergy/intolerance to all study medications increased slightly 
from 1995 to 2004, but was quite low in all cases. Rates of 
allergy/intolerance to medications in the most recent study 
year (2004) were as follows: ACE inhibitors/ARB’s 3.3%, 
aspirin 4.0%, aldosterone antagonists 0.1%, beta blockers 
0.8%, and lipid-lowering medications 0.9%.
Patient characteristics and receipt of selected cardiac 
medications
Women, the oldest patients (≥ 85 years of age), patients ex-
periencing HF for the first time, patients with higher ejection 
fractions, patients with a history of anemia or chronic lung 
disease, and patients presenting with generalized weakness 
were the most likely to be discharged without either a beta 
blocker or an angiotensin pathway inhibitor. In 1995, 60.3% 
of patients were discharged on medications from at least 1 
of the 2 recommended drug classes for the management of 
ADHF and 8.8% were discharged on medications from both 
drug classes; these percentages were 81.9% and 40.4%, re-
spectively, in 2004 (P < 0.001).
After controlling for a variety of demographic and clini-
cal factors, patients hospitalized in the initial study year of 
1995, women, patients with a first hospitalization for ADHF, 
those with impaired renal function, a history of anemia or 
COPD, and those who presented with edema were signifi-
cantly less likely to have received effective HF therapies at 
the time of hospital discharge than respective comparison 
groups. While relatively similar factors were associated with 
the failure to be treated with effective HF therapies in our 
initial (1995) and most recent (2004) study years, there were 
appreciably fewer demographic and clinical factors associ-
ated with the failure to receive these therapies in 2004.
Discussion
  
The results of this community-wide study of patients hos-
pitalized with ADHF demonstrate a marked increase in the 
use of beta blockers and angiotensin pathway inhibitors, in 
accordance with ACC/AHA Guidelines, and a decrease in 
the use of therapies that have not been shown to reduce pa-
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tient mortality. Older patients, women, patients with a new 
presentation of HF, patients with non-cardiac co-morbidities, 
and patients presenting with generalized symptoms were the 
least likely to be treated with effective HF medications. Al-
though fewer than 1 in every 5 patients with HF was dis-
charged without a beta blocker or angiotensin pathway in-
hibitor in 2004, only 2 out of every 5 patients with ADHF 
were discharged on both of these recommended medication 
classes. These results suggest that there are opportunities for 
further improvement in the medical management of patients 
with ADHF. Importantly, the increased use of recommended 
medications documented in this study is coincident with a 
marked decrease in the HF hospitalization rate that has been 
observed nationally [20].
Trends in HF medication prescribing practices
Several studies have documented a change in medication 
prescribing patterns for patients with HF following the ini-
tial publication of ACC/AHA HF guidelines in 1995 and 
following more recent updates. The Cardiovascular Health 
Study evaluated the use of discharge medications for elderly 
persons with incident HF between 1989 and 2000 in 4 large 
U.S. communities [25]. In this study, there was an average 
increase in beta blocker use of 2.4% annually between 1989 
and 2000.
A study based on data from the Acute Decompensated 
Heart Failure National Registry (ADHERE) examined quar-
terly trends in treatment practices in 159,168 HF hospitaliza-
tions from 2002 to 2004 [26]. Over this period, beta blocker 
use increased by approximately 20%. The use of angiotensin 
pathway inhibitors and diuretics was relatively unchanged, 
the use of aldosterone antagonists increased slightly, and 
the use of digoxin decreased significantly. In 2004, approxi-
mately 62% of HF cases were treated with an angiotensin 
pathway inhibitor prior to hospitalization, compared with 
55% in our study, while 69% were treated with a beta block-
er, compared with 68% in our study.
The results of the present study confirm the findings of 
earlier investigations, which showed improved adherence to 
ACC/AHA guidelines. Our study extends prior results by 
demonstrating continuous improvement in the prescribing of 
recommended HF therapies between 1995 and 2004, follow-
ing initial issuance of these guidelines in 1995. The present 
study also extends prior work by evaluating the combination 
use of effective HF therapies, as well as the effect of medica-
tion contraindications, demographic, and clinical factors on 
prescribing practices.
The observed increases in the use of effective cardiac 
therapies for HF is notable in the context of the significant 
decrease in the hospitalization rate for HF observed nation-
ally in more than 55 million Medicare beneficiaries hospital-
ized with HF between 1998 and 2008 [20]. The decreased 
rate of HF hospitalizations over this period stands in contrast 
with the results of prior studies, such as the Framingham 
Heart Study (1970 - 1999) [18], and Olmsted County, MN, 
study (1979 - 2000) [19], which covered periods prior to the 
issuance of the ACC/AHA HF guidelines, and demonstrated 
stable rates of HF-related hospitalizations. While we cannot 
directly assess the contribution of improved medical therapy 
to the recent reduction in hospitalization rate for HF, it has no 
doubt played an important role.
Patient factors and receipt of cardiac therapies
In the limited studies that have examined patient character-
istics associated with the use of different HF therapies, the 
underuse of beneficial cardiac therapies has been previously 
related to older patient age, impaired renal function, and pre-
served left ventricular systolic function. In the current study, 
patients of advanced age, women, those with selected co-
morbidities, and those with a first episode of ADHF were 
least likely to receive effective treatment modalities.
Although avoidance of beta-blockers in patients with 
asthma or COPD may be prudent, a substantial proportion of 
these patients can tolerate careful titration of beta-blockers 
without respiratory compromise. Underutilization of effec-
tive therapies in patients with a first episode of HF may rep-
resent a missed opportunity to prevent recurrent events.
Our findings support the increasing enthusiasm by qual-
ity control agencies and hospitals for the development of 
comprehensive guidelines for the management of patients 
with acute and chronic HF. These guidelines strongly recom-
mend the use of both pharmacologic and non-pharmacologic 
management, emphasize close patient follow-up, and stress 
patient education and involvement.
Study strengths and limitations
The primary strengths of this study were the large, popula-
tion-based sample of patients with independently validated 
ADHF, detailed information on out-patient, in-hospital, and 
discharge medications, and extensive information on patient 
demographic and clinical characteristics. Limitations of this 
study included a predominantly Caucasian population from 
a single region in central New England, inability to validate 
patient adherence to the medications examined, and lack of 
information regarding why certain patient subgroups may 
have been undertreated with effective HF treatment regi-
mens. The inability to more systematically examine the use 
of the therapies under study in relation to whether patients 
had preserved or reduced EF findings, since only one third 
of patients had EF data available, is an acknowledged limita-
tion of this investigation.
Conclusions
In this community-wide study, the use of recommended 
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therapies for HF increased markedly following issuance of 
the ACC/AHA HF guidelines. While progress in the man-
agement of these high risk patients has been substantial, and 
recent data shows an encouraging decrease in the rate of hos-
pitalization for HF, there remains considerable opportunity 
for more optimal medical treatment of patients with HF.
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